Member Info for Sisu

Likely batch verifications (against product spec.). End of April was noted. It's getting real close guys...

https://twitter.com/mologic/status/1387404221985734657?s=19

Cheers Simon, great analysis. I have just bought a few thousand more shares.

Unfortunately, I can't help you if you're disappointed with a one year turn-around time for the best-in-market LFT test during a pandemic with no direct company experience in the field previous to the pandemic.

Just take a back step, best in class test (I say this until I see something that shows me otherwise!) headed by little old Avacta. Novo Nordisk (to name one of the biggest fish) have a MCap of just shy of 171Billion USD. AVCT's is 843m USD. If AVCT have taken so long then why aren't there already much better tests in market than we are about to release within weeks?

Gkb, you also said "Yes the DeepVerge test collaboration, I know it's not their test but why not mention what's happening, or is it not worth mentioning? What's happening with that evaluation up at Aberdeen? Last I heard DeepVerge were using Aptamers anyway."

I below quote you a DeepVerge RNS from 17th March 2021

"In addition, under the clinical trial supervision of the Royal College of Surgeons, Ireland, 40 subjects, 16 of which were independently confirmed as COVID19 positive with PCR[iii] tests, provided breath samples that were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group")[iv] and Optimers ("Aptamer Group")[v] together the ("Binding Agents")."

I'm happy to engage in such conversations as I love to learn as much as possible of the companies I am involved in, I'd advise you doing so too! Anyway, I wish you all the best with your investment here. It's put a lot of people in to a greatly profitable position, I hope you are also one of those. Life changing, hopefully. :)

Gkb, twice you've said things and I've counterargued them and you've then agreed with me by saying you are aware of them and gone off on a sideways tangent? You said DeepVerge only used Aptamers and then knew that they also used Affimers?

If in doubt just take a look at the Innova instructions, the directions show you to brain-tickle.

P.S. Five trading days until May, how exciting to know we have the best product (also accounting for all variables including cost, ease of manufacturing, s/s, collection method etc.) coming to market that has a near limitless requirement for these tests. Also about to cement Affimers as a fantastic working tech, lock-in a place in future diagnostic approaches to pandemics and whilst we're at it, globally advertise them/the company too. Think about the money and resource companies like Roche have, and this test has proven itself to blow theirs out of the water!

Gkb.

https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/C0873_i_SOP_LFD-rollout-for-asymptomatic-staff-testing_phase-2-trusts-v1.1_16-nov20.pdf

Page 3 -" The manufacturer’s instructions for use (IFU) are included in the box and are detailed and very technical. These do not need to be followed as NHS staff will use the test in a slightly different way, which has been agreed with experts, discussed with MHRA, and the manufacturer informed. This is particularly in relation to use of the test for asymptomatic people, self-administration of the test, and the use of nasal swab inside the lower part of both nostrils. The rest of the process (ie the way the test is performed, and the results are interpreted) is the same as set out in the manufacturer’s instructions"

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/943187/S0925_Innova_Lateral_Flow_SARS-CoV-2_Antigen_test_accuracy.pdf

48.89% sensitivity. Yuck

Freudian slip if I've ever heard one.

Hi gkb, DeepVerges test utilises both Aptamers and Affimers in collaboration.

In regard to DHSC home testing of Innova, Innova was validated as a brain-tickler - there are lots of reports out there showing how when used as AN (as AVCT are utilising) the S/S is significantly less than reported. It was designed and tested as a brain-tickler, UK Gov wanted to keep the quantity high so took the decision to allow a very ineffective test, within its unverified collection method, to be utilised. There is a higher quantity of the viral load in the brain-tickler region than there is AP, wouldn't surprise me if we saw 100%/100% s/s with AVCT using that testing method and then passing it through underhand as AP.

https://presentations.investormeetcompany.com/investor-meet-company/AVACTA-GROUP-PLC-Full-year-12-month-results-ending-on-31st-Dec-2020?bmid=1659dd036676

https://twitter.com/avacta/status/1385531622351593474

The good stuff is from 00:01s to 01h01m! :)

If NCYT are partnering with someone, their s/s will very unlikely be market leading especially without the amount of time tweaking required to refine the s/s. Good luck to them whatever they make, I'm sure it'll sell.

Although what a great plot twist if AffiRx's first customer is NCYT and they're using our magic beans for their saliva test :-) We will harpoon a few big fish that want a slice of the LFT pie I am sure, what better way than to utilise the most specific of technologies (oh and 100% sensitive to infectious level viral loads, too!).

I've genuinely become apathetic towards the SP. I will re-tune in to my emotion of it when I feel some of the potential has been realised. That will be when Affimers are working their magic after millions of people have shoved a swab up their nose, and re-agents are being distributed around the world.

Vaccine-gate caused the SP to drop to below 100p, of which the SP is currently 2.5x of, despite huge reports stating how critical testing will be and will need to work along side vaccination. AIM is very irrational, the more it's understood the easier it is to set your position and only review when you feel it is best time to do so for any given reason.

I listened to every word and picked up on no head-scratching comments that may be concerned. Just the fact LFT works, very well, demand is absolutely massive and AVCT are directly aware of that. 5M p/m as a low end figure of manufacturing capacity in UK is not concerning for me, given EU and RoW were signalled as potential requirements also. We also wouldn't be hinted at 30m if it wasn't a reasonable goal.

Great presentation, btw.

All but seemingly confirmed UK Gov involvement by iterating he can't put concrete figure on the upper end of manufacturing capacity due to ongoing nature of Government investment for (UK Capacity wise)- in direct relation to our manufacturing capacity.

Oooh this is a good presentation!

Completely. To me it's a huge strike of intelligence if someone can explain such complex matters with such ease and clarity - not many of us here paid attention in our science lessons I'm sure but he certainly knows how to elaborate for all parties to understand. Also get the feeling he could sell ice to an Eskimo.

FWIW Medusa have been quoted to be gunning for "up to 100m tests per month"*, 50m at Wirral as you say and 50m seemingly elsewhere. One would assume Madrid/EU to capture a piece of the marketplace there that they already have themselves within. Of course pinch of salt needs to be taken with all manufacturing capacity aims.

GAD are aiming at 250m per year as far as I'm aware (so a little under 21m / month)

* https://www.lancs.live/news/lancashire-news/founders-lancashire-based-boohoo-launch-18952163

Also, jdt, as an aside but on the LFT v PCR debate in this context. Regarding sensitivity rather than specificity/false negatives, an important factor is the 'infectiousness' scale that AS has banged on the drum of for so long. PCR, if positive, will say so even if it picks it up on one of the last cycles; where you have the tiniest of viral load and aren't near an infectious state.

AVCT's LFT is 100% at these levels and that is so important it can't be said enough, even if that proves to be 99% or 99.99% in larger scales - it's a monumental step forward in comparison to other LFT's we have vision of. I would feel confident on a flight knowing everyone had taken a solitary LFT with this s/s, let alone 2.

Based on 99% exactly, the chances of 2 consecutive false positives (out of only 2) is 1 in 10,000. 1% of 1% essentially. With the cost 7fold cheaper, based on £5 cost price, than the CHEAPEST PCR (not to mention so much quicker) and 40fold cheaper than the higher end cost of PCR - it's a huge huge win in favour of LFT's. Very sensitive and specific ones at that.

AVCT specificity actually was 99.019607843137% if we're being meticulous so will affect less than 1 in 10,000. :-)

https://twitter.com/sensedx1/status/1268463867753123842

Wonder how much they paid for a good bit of PR. They've been pressing the PR since March last year and are currently still plenty of months away. Just hunting for more investors seemingly, it looks a great product but the cost for something that may be marginally more sensitive/specific than AVCT's LFT - not ideal.

Rumour has it Deeks was the 102nd to be tested and flagged as a false positive. He scampered around the hospital swiping every surface and stuffing his fingers up his nose - he's over the moon to have pushed our specificity down from 100% to 99%. Still market leading but every little helps Deeks.

The sovereign LFT definitely will be utilising an app of sorts to display/log results.

UK Gov LFT DPS Spec: "4.2 To ensure each Test is uniquely identifiable, we currently require (as at March 2021) the providers of the Test to have the capability to be able to print, or add as a label, a QR Code with a matching unique alphanumeric ID sequence onto the cassette housing the Test"